ARIAD announces long-term molecular response data on Ponatinib ARIAD Pharmaceuticals announced updated molecular response data from its Phase 1 and pivotal Phase 2 trials of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The studies now show that 51% of chronic-phase CML patients in the Phase 1 trial achieved a major molecular response with a median follow-up of 30 months, and 34% of chronic-phase patients achieved MMR in the PACE trial with a median follow-up of 15 months.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Subscribe for More Information